A different functional assay involving an alternative pathway regulated by CD32b ligands may have demonstrated a measurable consequence of reduced B cell CD32b expression that could contribute to the pathogenesis of MS in females. The gene discussed is FCGR2B; the disease is myeloid sarcoma.